| Theme | Recent progress in calcium/phosphate metabolism and Klotho | |
|---|---|---|
| Title | Pharmacological effects and application of anti-FGF23 neutralizing antibodies | |
| Publish Date | 2009/04 | |
| Author | Hisashi Hasegawa | Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Company, Limited |
| [ Summary ] | Fibroblast growth factor 23 (FGF23) has been determined to be a phosphate-regulating hormone. Several types of hypophosphatemia have recently been reported to be caused by excess FGF23 activity. It was found out that anti-FGF23 neutralizing antibodies ameliorated hypophosphatemic rickets/osteomalacia (XLH) caused by excess FGF23 activity in Hyp mice. Although current therapies for XLH consist of replenishment of phosphates, it is hoped that anti-FGF23 neutralizing antibodies will provide new therapies for XLH, based disease etiology. | |